• REDEMPLO® (plozasiran) is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS), diagnosed either based on clinical symptoms alone or confirmed with a genetic test
  • People living with this rare disease have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, often resulting in a reduced quality of life
  • European marketing authorisation is based on positive results from the Phase 3 PALISADE study where plozasiran significantly reduced median fasting triglyceride levels at the 25 mg recommended dose from baseline to Month 10, compared to placebo (p <0.0001)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that people in Germany who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) are the among first in the European Union to have a new treatment option to reduce dangerously high levels of triglycerides (TGs, a type of fat) in their bloodstream. Following its marketing authorization by the European Commission in June 2026, REDEMPLO® (plozasiran) is now listed in the Lauer-Taxe® database and thus able to be prescribed, dispensed and reimbursed in Germany. REDEMPLO is authorized for use alongside diet, by adults diagnosed with FCS based on clinical symptoms or a genetic test, unlike other treatments that can be used only after genetic confirmation. It is taken as a subcutaneous injection once every three months.